Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AIDS VACCINE RESEARCH GROUPS FUNDED BY NIAID

Executive Summary

AIDS VACCINE RESEARCH GROUPS FUNDED BY NIAID will focus on developing a product to block simian immunodeficiency virus (SIV) in monkeys. In a March 7 release announcing the awards, the National Institute of Allergy and Infectious Diseases explained that "once an effective monkey vaccine has been designed using SIV, scientists can replace key parts of that model vaccine with matching ones from HIV." NIAID is funding five new National Cooperative Vaccine Development Groups for AIDS. Each group is funded for five years and will receive more than $4 mil. in the first year. NIAID awarded the first six groups last April. The groups are led by a principal investigator and include scientists from academia, industry and government. The principal investigators receiving the new grants are: Dennis Panicali, Applied bioTechnology; Wayne Hockmeyer, Molecular Vaccines, Inc.; Michael Murphey-Corb, Delta Regional Primate Center in Covington, Louisiana; Richard Compans, University of Alabama-Birmingham; and Arsene Burny, University of Brussels, Belgium. Four of the five groups will study SIV to find clues to design an HIV vaccine. The group headed by Molecular Vaccines will work with HIV alone. NIAID noted that SIV shares about 40-50% of its genetic structure with HIV, "which makes the immune response to the two viruses remarkably similar." The institute said vaccine researchers will "identify and tease out SIV molecules that stimulate the body's immune defenses to prevent the virus from establishing an infection. Researchers will then construct prototype vaccines from these components and test them for their ability to block SIV infection in monkeys." NIAID said parallel experiments will be conducted using HIV. Applied bioTechnology announced in a same-day release that it will develop prototype AIDS vaccines by "inserting one or more genes from HIV into vaccinia, the virus used as the basis of the smallpox vaccine." The company said the vaccinia "serves as a carrier for the HIV genes, and proteins for which they encode, and that are intended to stimulate an immune response." In addition, Applied bioTechnology is developing SIV vaccinia prototypes "containing antigens comparable to the HIV vaccine prototypes." The Applied bioTechnology group includes scientists at Harvard Medical School's New England Regional Primate Research Center and the University of Massachusetts Medical Center in Worcester.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel